RUNX1 and pancreatic ductal adenocarcinoma: explored the YTHDC1/miR‐30d/RUNX1 pathway in pancreatic ductal adenocarcinoma, showing that YTHDC1 promotes miR‐30d biosynthesis, which targets RUNX1 to regulate SLC2A1 and HK1 expression, thereby inhibiting aerobic glycolysis.